EconPapers    
Economics at your fingertips  
 

Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors

Benjamin Israelow, Gavriel Mullokandov, Judith Agudo, Marion Sourisseau, Ali Bashir, Andres Y. Maldonado, Arvin C. Dar, Brian D. Brown () and Matthew J. Evans ()
Additional contact information
Benjamin Israelow: Icahn School of Medicine at Mount Sinai
Gavriel Mullokandov: Icahn School of Medicine at Mount Sinai
Judith Agudo: Icahn School of Medicine at Mount Sinai
Marion Sourisseau: Icahn School of Medicine at Mount Sinai
Ali Bashir: Icahn School of Medicine at Mount Sinai
Andres Y. Maldonado: Icahn School of Medicine at Mount Sinai
Arvin C. Dar: Icahn School of Medicine at Mount Sinai
Brian D. Brown: Icahn School of Medicine at Mount Sinai
Matthew J. Evans: Icahn School of Medicine at Mount Sinai

Nature Communications, 2014, vol. 5, issue 1, 1-11

Abstract: Abstract Hepatitis C virus (HCV) replication is dependent on a liver-specific microRNA (miRNA), miR-122. A recent clinical trial reported that transient inhibition of miR-122 reduced viral titres in HCV-infected patients. Here we set out to better understand how miR-122 inhibition influences HCV replication over time. Unexpectedly, we observed the emergence of an HCV variant that is resistant to miR-122 knockdown. Next-generation sequencing revealed that this was due to a single nucleotide change at position 28 (G28A) of the HCV genome, which falls between the two miR-122 seed-binding sites. Naturally occurring HCV isolates encoding G28A are similarly resistant to miR-122 inhibition, indicating that subtle differences in viral sequence, even outside the seed-binding site, greatly influence HCV’s miR-122 concentration requirement. In addition, we found that HCV itself reduces miR-122’s activity in the cell, possibly through binding and sequestering miR-122. Our study provides insight into the interaction between miR-122 and HCV, including viral adaptation to reduced miR-122 bioavailability, and has implications for the development of anti-miR-122-based HCV drugs.

Date: 2014
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms6408 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6408

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms6408

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

 
Page updated 2025-03-19
Handle: RePEc:nat:natcom:v:5:y:2014:i:1:d:10.1038_ncomms6408